Our History
For more than a decade, Crux Biolabs have been an Australian leader.
Crux Biolabs dedicates itself to being an extension of the research and testing team no matter how big or small. Efficient, agile, thorough, we pride ourselves on building long standing relationships with our clients and are heavily investing in growing our team and laboratory capacity to support the high demand from our global sponsors to test and deliver time and time again.
2011
- Company established, initially focused entirely on domestic ELISA kit manufacturing for the academic research sector
2016
- Added multiplex service offering through the procurement of a Luminex platform
2017
- Expansion of client base to include biotech and pharma customers in addition to traditional academic research sector
- Changed name from elisakit.com to Crux Biolabs
2018
- Implemented ISO/IEC-accredited QMS
- Expansion into clinical trial lab services
- Expansion of service offering to include PBMC processing and flow cytometry
2019
- Obtained NATA ISO 17025 accreditation
- Established partnership with global lab network
- Established partnerships with local accredited labs in oncology and virology
2020
- Relocation to a 460 sqm facility in Bayswater (~4x the size of the previous facility)
- Expansion of client base to include global sponsors
- Shift in focus to building clinical trial pipeline
2021
- Growth in the lab team to support high demand of global sponsors
- Procurement of ELIspot instrument to provide the full range of immunology services
2022
- Addition of MSD platform and nucleic acid extraction
- Expand lab facility by ~145%
- Plans to upgrade immunoassays to GCLP accreditation and add Analytical Chemistry for PK services